Scrip
Novartis's Ilaris looks promising for gout
28 June 2010
Katie McQue
Please Login to read the full article.
28 June 2010
Katie McQue
katie.mcque@informa.com
Novartis's injectable interleukin-1 blocker Ilaris (canakinumab) significantly reduced the rate of acute flares of gout in patients who are starting therapy with a uric acid lowering therapy compared with the anti-inflammatory colchicine, showed a Phase II study presented at the recent European League...
Please Login to read the full article.
RELATED CONTENT
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
